Management and Outcomes of Pediatric Lymphatic Malformations: A Systematic Review From the APSA Outcomes and Evidence-Based Practice Committee
Topic overview
Systematic review of 202 studies examining pediatric lymphatic malformation treatment found sclerotherapy achieves >90% response rates for macrocystic lesions, while sirolimus serves as effective adjunct therapy. Optimal outcomes require individualized, multidisciplinary approach combining medical therapy, sclerotherapy, and surgery based on lesion characteristics.
Key takeaways
- Sclerotherapy achieves >90% partial or complete response and is most effective for macrocystic lymphatic malformations
- Sirolimus can be used as adjunct therapy with procedures or as primary treatment for extensive lymphatic malformations
- Multi-modal treatment tailored to lesion size, extent, and type yields best outcomes for pediatric lymphatic malformations
- Multidisciplinary team approach is recommended to individualize treatment strategy for each patient
- Current evidence for lymphatic malformation management is moderate quality; treatment choice depends on lesion characteristics
Comments